{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:14:51Z","timestamp":1793812491030,"version":"4.6.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T00:00:00Z","timestamp":1581897600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T00:00:00Z","timestamp":1581897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Mega-projects of National Science Research for the 13th Five-Year Plan","award":["2017ZX10201101"],"award-info":[{"award-number":["2017ZX10201101"]}]},{"name":"the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences","award":["2018PT31042"],"award-info":[{"award-number":["2018PT31042"]}],"id":[{"id":"https:\/\/ror.org\/02drdmm93","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation","doi-asserted-by":"crossref","award":["81871637"],"award-info":[{"award-number":["81871637"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Low level viremia (LLV) often occurs during antiretroviral therapy (ART) against HIV-1. However, whether LLV increases the risk of virologic failure (VF) is controversial because of the non-uniform definitions of LLV and VF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A long-term first line regimen ART cohort from 2002 to 2018 from Shenyang, northeast China, was retrospectively studied. All participants were followed up every 3 to 6\u2009months to evaluate the treatment effect. The high-risk LLV subgroups leading to VF (with strict standards) were explored with Cox proportional hazards model and linear mixed-effect model. The association factors of high-risk LLV were further explored using multivariate logistic regression analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 2155 HIV-1 infected participants were included; of these, 38.7% showed LLV. Both high level LLV (HLLV) and any other level LLV coupled with high level blip (HLB) showed higher risk of VF (hazards ratios, HR\n                      <jats:sub>HLLV<\/jats:sub>\n                      \u2009=\u20095.93, and HR\n                      <jats:sub>HLB<\/jats:sub>\n                      \u2009=\u20092.84,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009\u00a00.05 respectively). Moreover, HR increased with prolonged duration of LLV. Independent factors associated with high-risk LLV included the zenith baseline viral load (VL) above 6 log copies\/ml (aOR\u2009=\u20093.49,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002), nadir baseline CD4\u2009+\u2009T cell counts below 200 cells\/mm\n                      <jats:sup>3<\/jats:sup>\n                      (aOR\u2009=\u20091.78,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.011), Manchu (aOR\u2009=\u20092.03,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003), ART over 60\u2009months (aOR\u2009=\u20091.81,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004), AZT\u2009+\u20093TC\u2009+\u2009NVP (aOR\u2009=\u20092.26,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009\u00a00.001) or DDI-based regimen (aOR\u2009=\u20099.96,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002), and subtype B\u2032 infection (aOR\u2009=\u20098.22,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In case of VF with strict standards, high-risk LLV leading to VF includes VL above 400 copies\/ml, occurring at least once. Serious laboratory indicators or advanced stage of infection, long term ART and subtype B\u2032 infection might also predict the occurrence of high-risk LLV.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-020-4837-y","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T10:36:33Z","timestamp":1582022193000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Factors associated with high-risk low-level viremia leading to virologic failure: 16-year retrospective study of a Chinese antiretroviral therapy cohort"],"prefix":"10.1186","volume":"20","author":[{"given":"Tong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,17]]},"reference":[{"key":"4837_CR1","doi-asserted-by":"crossref","unstructured":"Paintsil E, Martin R, Goldenthal A, Bhandari S, Andiman W, Ghebremichael M. Frequent Episodes of Detectable Viremia in HIV Treatment-Experienced Children is Associated with a Decline in CD4+ T-cells Over Time. J AIDS Clin Res. 2016;7(4):565.","DOI":"10.4172\/2155-6113.1000565"},{"issue":"2","key":"4837_CR2","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/S1473-3099(17)30681-3","volume":"18","author":"LE Hermans","year":"2018","unstructured":"Hermans LE, Moorhouse M, Carmona S, et al. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided south African treatment programmes: a multicentre cohort study. Lancet Infect Dis. 2018;18(2):188\u201397.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"4837_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/QAI.0000000000001678","volume":"78","author":"E Bernal","year":"2018","unstructured":"Bernal E, Gomez JM, Jarrin I, et al. Low-level Viremia is associated with clinical progression in HIV-infected patients receiving Antiretroviral treatment. J Acquir Immune Defic Syndr. 2018;78(3):329\u201337.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"4837_CR4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/jpids\/piy041","volume":"8","author":"Ruth Pereira","year":"2018","unstructured":"Pereira R, Ludwig DA, Mathew S, et al. Predicting viral failure in human immunodeficiency virus perinatally infected youth with persistent low-level Viremia on highly active Antiretroviral Therapy. J Pediatr Infect Dis Soc. 2019;8(4):303\u20139.","journal-title":"Journal of the Pediatric Infectious Diseases Society"},{"key":"4837_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s12879-016-1628-6","volume":"16","author":"E Sorstedt","year":"2016","unstructured":"Sorstedt E, Nilsson S, Blaxhult A, et al. Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels. BMC Infect Dis. 2016;16:305.","journal-title":"BMC Infect Dis"},{"issue":"12","key":"4837_CR6","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1093\/cid\/ciz129","volume":"69","author":"Christie Joya","year":"2019","unstructured":"Joya C, Won SH, Schofield C, et al. Persistent low-level Viremia while on Antiretroviral Therapy is an independent risk factor for Virologic failure. Clin Infect Dis. 2019;69(12):2145\u201352.","journal-title":"Clinical Infectious Diseases"},{"issue":"5","key":"4837_CR7","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/cid\/ciy989","volume":"69","author":"Allahna Esber","year":"2018","unstructured":"Esber A, Polyak C, Kiweewa F, et al. Persistent low level viremia predicts subsequent virologic failure. Is it time to change the 3rd 90? Clin Infect Dis. 2019;69(5):805\u201312.","journal-title":"Clinical Infectious Diseases"},{"issue":"8","key":"4837_CR8","doi-asserted-by":"publisher","first-page":"e9969","DOI":"10.1097\/MD.0000000000009969","volume":"97","author":"AN Dravid","year":"2018","unstructured":"Dravid AN, Natrajan K, Kulkarni MM, et al. Discordant CSF\/plasma HIV-1 RNA in individuals on virologically suppressive antiretroviral therapy in Western India. Medicine. 2018;97(8):e9969.","journal-title":"Medicine."},{"key":"4837_CR9","unstructured":"Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. World Health Organization. Available at: https:\/\/www.who.int\/hiv\/pub\/guidelines\/keypopulations-2016\/en\/9789241511124-eng.pdf. Accessed 1 July 2016."},{"issue":"11","key":"4837_CR10","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1093\/jac\/dkx272","volume":"72","author":"B Pernas","year":"2017","unstructured":"Pernas B, Rego-Perez I, Tabernilla A, et al. Plasma mitochondrial DNA levels are inversely associated with HIV-RNA levels and directly with CD4 counts: potential role as a biomarker of HIV replication. J Antimicrob Chemother. 2017;72(11):3159\u201362.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"4837_CR11","doi-asserted-by":"publisher","first-page":"19246","DOI":"10.7448\/IAS.17.1.19246","volume":"17","author":"B Torres","year":"2014","unstructured":"Torres B, Guardo AC, Leal L, et al. Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation. J Int AIDS Soc. 2014;17(1):19246.","journal-title":"J Int AIDS Soc"},{"issue":"2","key":"4837_CR12","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1128\/JCM.02461-13","volume":"52","author":"LC Swenson","year":"2014","unstructured":"Swenson LC, Cobb B, Geretti AM, et al. Comparative performances of HIV-1 RNA load assays at low viral load levels: results of an international collaboration. J Clin Microbiol. 2014;52(2):517\u201323.","journal-title":"J Clin Microbiol"},{"key":"4837_CR13","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services. Available at: http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf. Accessed 27 March 2018"},{"issue":"4","key":"4837_CR14","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1093\/jac\/dkv433","volume":"71","author":"B Pernas","year":"2016","unstructured":"Pernas B, Grandal M, Pertega S, et al. Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART? J Antimicrob Chemother. 2016;71(4):1051\u20135.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"4837_CR15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/QAI.0b013e3182567a57","volume":"60","author":"F Maggiolo","year":"2012","unstructured":"Maggiolo F, Callegaro A, Cologni G, et al. Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure. J Acquir Immune Defic Syndr. 2012;60(5):473\u201382.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"4837_CR16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/hiv.12600","volume":"19","author":"L Ryom","year":"2018","unstructured":"Ryom L, Boesecke C, Bracchi M, et al. Highlights of the 2017 European AIDS clinical society (EACS) guidelines for the treatment of adult HIV-positive persons version 9.0. HIV Med. 2018;19(5):309\u201315.","journal-title":"HIV Med."},{"issue":"4","key":"4837_CR17","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3851\/IMP1564","volume":"15","author":"S Zhang","year":"2010","unstructured":"Zhang S, van Sighem A, Gras L, et al. Clinical significance of transient HIV type-1 viraemia and treatment interruptions during suppressive antiretroviral treatment. Antivir Ther. 2010;15(4):555\u201362.","journal-title":"Antivir Ther"},{"issue":"8","key":"4837_CR18","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1093\/infdis\/jis104","volume":"205","author":"JT Grennan","year":"2012","unstructured":"Grennan JT, Loutfy MR, Su D, et al. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis. 2012;205(8):1230\u20138.","journal-title":"J Infect Dis"},{"issue":"6","key":"4837_CR19","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3851\/IMP2949","volume":"20","author":"MA Vandenhende","year":"2015","unstructured":"Vandenhende MA, Perrier A, Bonnet F, et al. Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy (ANRS C03 cohort study). Antivir Ther. 2015;20(6):655\u201360.","journal-title":"Antivir Ther"},{"issue":"10","key":"4837_CR20","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1093\/cid\/cit529","volume":"57","author":"C Laprise","year":"2013","unstructured":"Laprise C, de Pokomandy A, Baril JG, Dufresne S, Trottier H. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. Clin Infect Dis. 2013;57(10):1489\u201396.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"4837_CR21","doi-asserted-by":"publisher","first-page":"e50065","DOI":"10.1371\/journal.pone.0050065","volume":"7","author":"TJ Henrich","year":"2012","unstructured":"Henrich TJ, Wood BR, Kuritzkes DR. Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 copies\/mL. PLoS One. 2012;7(11):e50065.","journal-title":"PLoS One"},{"issue":"2","key":"4837_CR22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3851\/IMP2815","volume":"20","author":"N Boillat-Blanco","year":"2014","unstructured":"Boillat-Blanco N, Darling KEA, Schoni-Affolter F, et al. Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV Cohort study. Antivir Ther. 2014;20(2):165\u201375.","journal-title":"Antivir Ther"},{"key":"4837_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12981-016-0100-4","volume":"13","author":"A Farmer","year":"2016","unstructured":"Farmer A, Wang X, Ganesan A, et al. Factors associated with HIV viral load \u201cblips\u201d and the relationship between self-reported adherence and efavirenz blood levels on blip occurrence: a case-control study. AIDS Res Ther. 2016;13:16.","journal-title":"AIDS Res Ther"},{"issue":"12","key":"4837_CR24","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1093\/jac\/dkw307","volume":"71","author":"E Quiros-Roldan","year":"2016","unstructured":"Quiros-Roldan E, Raffetti E, Castelli F, et al. Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: a MASTER cohort study. J Antimicrob Chemother. 2016;71(12):3519\u201327.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"4837_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/QAI.0000000000000125","volume":"66","author":"ST Wright","year":"2014","unstructured":"Wright ST, Hoy J, Mulhall B, et al. Determinants of viremia copy-years in people with HIV\/AIDS after initiation of antiretroviral therapy. J Acquir Immune Defic Syndr. 2014;66(1):55\u201364.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"4837_CR26","unstructured":"AIDS and Hepatitis C Professional Group SoID, Chinese Medical Association, Chinese Center for Disease Control and Prevention. Chinese guidelines for diagnosis and treatment of HIV\/AIDS (2018). Zhonghua Nei Ke Za Zhi. 2018;57(12):867\u2013884."},{"issue":"2","key":"4837_CR27","doi-asserted-by":"publisher","first-page":"ofy032","DOI":"10.1093\/ofid\/ofy032","volume":"5","author":"A Ruggiero","year":"2018","unstructured":"Ruggiero A, Cozzi-Lepri A, Beloukas A, et al. Factors Associated With Persistence of Plasma HIV-1 RNA During Long-term Continuously Suppressive Firstline Antiretroviral Therapy. Open Forum Infect Dis. 2018;5(2):ofy032.","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"4837_CR28","doi-asserted-by":"publisher","first-page":"E349","DOI":"10.1016\/S2352-3018(17)30066-8","volume":"4","author":"A Trickey","year":"2017","unstructured":"Trickey A, May MT, Vehreschild JJ, et al. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet Hiv. 2017;4(8):E349\u201356.","journal-title":"Lancet Hiv"},{"issue":"11","key":"4837_CR29","doi-asserted-by":"publisher","first-page":"e1002432","DOI":"10.1371\/journal.pmed.1002432","volume":"14","author":"AJ Szubert","year":"2017","unstructured":"Szubert AJ, Prendergast AJ, Spyer MJ, et al. Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: observational analyses within the randomised ARROW trial. PLoS Med. 2017;14(11):e1002432.","journal-title":"PLoS Med"},{"issue":"2","key":"4837_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/cid\/ciy463","volume":"68","author":"HF Gunthard","year":"2019","unstructured":"Gunthard HF, Calvez V, Paredes R, et al. Human immunodeficiency virus drug resistance: 2018 recommendations of the international antiviral society-USA panel. Clin Infect Dis. 2019;68(2):177\u201387.","journal-title":"Clin Infect Dis"},{"key":"4837_CR31","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jcv.2016.07.007","volume":"82","author":"M Zaccarelli","year":"2016","unstructured":"Zaccarelli M, Santoro MM, Armenia D, et al. Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA. J Clin Virol. 2016;82:94\u2013100.","journal-title":"J Clin Virol"},{"issue":"6","key":"4837_CR32","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1093\/infdis\/jiw085","volume":"214","author":"K Buchacz","year":"2016","unstructured":"Buchacz K, Lau B, Jing Y, et al. Incidence of AIDS-defining opportunistic infections in a multicohort analysis of HIV-infected persons in the United States and Canada, 2000-2010. J Infect Dis. 2016;214(6):862\u201372.","journal-title":"J Infect Dis"},{"issue":"12","key":"4837_CR33","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1002\/gps.4667","volume":"32","author":"S Torvinen-Kiiskinen","year":"2017","unstructured":"Torvinen-Kiiskinen S, Tolppanen AM, Koponen M, et al. Antidepressant use and risk of hip fractures among community-dwelling persons with and without Alzheimer's disease. Int J Geriatr Psychiatry. 2017;32(12):e107\u201315.","journal-title":"Int J Geriatr Psychiatry"},{"key":"4837_CR34","unstructured":"Hernandez-Ramirez RU, Qin L, Lin H, et al. Association of immunosuppression and HIV viremia with anal cancer risk in persons living with HIV in the United States and Canada. Clin Infect Dis. 2019. (Online ahead of print)."},{"issue":"10","key":"4837_CR35","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1073\/pnas.0800050105","volume":"105","author":"S Palmer","year":"2008","unstructured":"Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A. 2008;105(10):3879\u201384.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"4837_CR36","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/cid\/ciy176","volume":"67","author":"Y Mutoh","year":"2018","unstructured":"Mutoh Y, Nishijima T, Inaba Y, et al. Incomplete recovery of CD4 cell count, CD4 percentage, and CD4\/CD8 ratio in patients with human immunodeficiency virus infection and suppressed Viremia during long-term Antiretroviral Therapy. Clin Infect Dis. 2018;67(6):927\u201333.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"4837_CR37","doi-asserted-by":"publisher","first-page":"e0180761","DOI":"10.1371\/journal.pone.0180761","volume":"12","author":"O Elvstam","year":"2017","unstructured":"Elvstam O, Medstrand P, Yilmaz A, Isberg PE, Gisslen M, Bjorkman P. Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment. PLoS One. 2017;12(7):e0180761.","journal-title":"PLoS One"},{"issue":"3","key":"4837_CR38","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/QAD.0000000000000544","volume":"29","author":"C Antiretroviral Therapy Cohort","year":"2015","unstructured":"Antiretroviral Therapy Cohort C, Vandenhende MA, Ingle S, et al. Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients. Aids. 2015;29(3):373\u201383.","journal-title":"Aids."},{"issue":"3","key":"4837_CR39","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/hiv.12413","volume":"18","author":"R Teira","year":"2017","unstructured":"Teira R, Vidal F, Munoz-Sanchez P, et al. Very low level viraemia and risk of virological failure in treated HIV-1-infected patients. HIV Med. 2017;18(3):196\u2013203.","journal-title":"HIV Med"},{"issue":"22","key":"4837_CR40","doi-asserted-by":"publisher","first-page":"12165","DOI":"10.1128\/JVI.77.22.12165-12172.2003","volume":"77","author":"M Di Mascio","year":"2003","unstructured":"Di Mascio M, Markowitz M, Louie M, et al. Viral blip dynamics during highly active Antiretroviral Therapy. J Virol. 2003;77(22):12165\u201372.","journal-title":"J Virol"},{"key":"4837_CR41","doi-asserted-by":"crossref","unstructured":"L FD, SA D, MM L, et al. Evaluation of tolerance of zidovudine-lamivudine-nevirapine combination in HIV 1 patients in Fann Teaching Hospital in Dakar. Bulletin de la Societe de pathologie exotique (1990). 2013;106(4):244\u2013247.","DOI":"10.1007\/s13149-013-0315-8"},{"key":"4837_CR42","unstructured":"Program NT. Toxicology and Carcinogenesis Studies of Mixtures of 3\u2032-Azido-3\u2032-Deoxythymidine (AZT), Lamivudine (3TC), and Nevirapine (NVP) (CAS Nos. 30516\u201387-1, 134678\u201317-4, 129618\u201340-2) in Genetically Modified C3B6.129F1-Trp53(tm1Brd) N12 Haploinsufficient Mice (in utero and postnatal gavage studies). National Toxicology Program genetically modified model report. 2013;undefined(16):1\u2013236."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-4837-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-020-4837-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-4837-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T11:17:25Z","timestamp":1613560645000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-4837-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,17]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4837"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-4837-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.16492\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.16492\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.16492\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.16492\/v4","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,17]]},"assertion":[{"value":"16 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the ethics committee of the First Affiliated Hospital of China Medical University. In addition, written informed consents were obtained from all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"147"}}